Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Silver Hammer Plans a Fall Surface and Drilling Exploration Program at the Silver Strand Project in Idaho, USA
Blue Jay Gold Intersects 14.0 m of 6.15 g/t Gold and 124 g/t Silver at Skukum Creek, Including 10.5 m of 7.84 g/t Gold and 154 g/t Silver
Blackrock Silver Receives Conditional Approval to List on The TSX and Establishes ATM Program as Longer Term Financial Alternatives
VanadiumCorp Continues the Third Year of Upstream Mineral Processing Research with Université de Sherbrooke
